As the therapeutic applications of CD19 CAR-T continues to grow in the relapsed/refractory setting of B-ALL and NHL, recognition, and management of associated toxicities in the standard of care setting is crucial. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.